In-silico Design of a Core Scaffold Pyrazolone Fused Heterocyclic Analogues as Dual Inhibitors Targeting Breast Cancer

Asian Journal of Pharmaceutical and Health Sciences,2021,11,2468,2468-2474.
Published:September 2021
Type:Original Article
Author(s) affiliations:

Sumathy Arunachalam1,*, Suresh Ramalingam2, Gowrishankar Narayanasamy Lachmanan1,

1Department of Pharmaceutical Chemistry, Prime College of Pharmacy, Palakkad, Kerala, INDIA.

2Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Chidambaram, Tamilnadu, INDIA.


In human breast cancers, the human epidermal development factor receptor (HER2) is a membrane tyrosine kinase that is overexpressed, and gene amplified. Pyrazolone fused heterocyclic moieties- carboxy methyl thiazolidinone, azetiditinone are significant DNA-intercalating agents here HER2 amplification and overexpression are linked to tumour cell proliferation and the pathway of instances in breast cancer. Few novel pyrazolone fused heterocyclic analogues are designed by the in-silico technique for their HER2 inhibitory action. Docking patterns of compounds 4B1-4C20 are carried out against HER2 (PDB id-3RCD) by using Schrodinger suit 2016-2. The affinity of binding was chosen based on the glide score. Many compounds were showing good hydrophobic and hydrogen bonding communication and association to hinder HER2. The derivatives 4B1-4C20 have significant glide scores in the scope of -4.745 to -7.571 compared to the standard Tamoxifen (-4.326). The in-silico screening properties are within the drug likeness. The results proved that this study gave a shred of evidence for the consideration of pyrazolone fused heterocyclic analogues are potential HER2 inhibitors. Among the compounds, 4B1-4C20 with significant glide scores may produce significant antibreast cancer activity and further in-vitro and in-vivo investigations may prove their therapeutic potential.

Scheme of the heterocyclic analogues fused with the core scaffold pyrazolone